James Montier, investment strategist, GMO
Investors normally overreact at extremes, James Montier, the value-investing guru who serves on GMO’s asset allocation team, tells Barron’s: they value stocks at “peak multiples on peak earnings and trough multiples on trough earnings”. But this time, it’s different. “Instead of following the collapse in earnings, the market is completely discounting [the risk] and operating as if there is nothing to worry about … and has priced in a V-shaped recovery.”
Yet even if earnings were to rebound, valuations still seem expensive. The economic expansion that ended with the Covid-19 crisis “was the longest but also the weakest economic recovery on record” and stockmarket gains have run ahead of earnings growth. That’s especially true in America, where rising valuations and share buybacks have been responsible for virtually all the superior performance of US stocks over the rest of the world, as Montier noted in a research report before the pandemic arrived in March.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
So most assets are making no allowance for the potential risks. Small caps look especially vulnerable to a severe recession, but even larger stocks that have done well so far – ie, big tech – “are probably only relative winners … Google and Facebook … aren’t going to see an increase in advertising revenue, so it’s not clear they win in an absolute sense”. Only emerging markets look cheap enough. “Everybody and their mother hates emerging markets,” which gives you a “much greater margin of safety.”
-
When is the “Bed & ISA” deadline? Cut-off dates for major investment platformsThe “Bed & ISA” deadline varies from provider to provider. We share a round-up of the key dates across major investment platforms
-
Spring Statement: what could Rachel Reeves say about pensions?The chancellor will deliver her Spring Statement on 26 March. We look at whether there will be any announcements on pensions that could affect savers or retirees
-
Why CEOs deserve a pay riseOpinion The CEOs of big companies often come under fire for being grossly overpaid. But the truth, as per some economists, is the opposite. Do they merit a pay rise?
-
Rolls-Royce stock jumps 15% – could it climb further?Aircraft-engine group Rolls-Royce’s CEO has been hailed as a hero for spearheading the firm’s recovery. And the future looks bright, says Matthew Partridge
-
The power of private marketsInterview Helen Steers, co-manager of the Pantheon International investment trust, tells MoneyWeek about the vast array of compelling opportunities in private equity
-
Vertex Pharmaceuticals is an uncommon opportunity in rare diseasesVertex Pharmaceuticals operates in a profitable subsector and is poised for further success
-
Global investors have overlooked these top tips in emerging marketsOpinion Chris Tennant, co-portfolio manager of Fidelity Emerging Markets, picks three attractive companies in emerging markets
-
King Coal has not been dethroned yet — should you buy?The demand for coal is only growing, yet investors don’t seem to want to take advantage of the opportunity, says Rupert Hargreaves
-
It’s time to start buying Europe again, says Merryn Somerset WebbOpinion Europe's stocks are cheap and the economic backdrop is starting to look cheerier, says Merryn Somerset Webb
-
Prosus to buy Just Eat for €4.1 billion as takeaway boom fadesFood-delivery platform Just Eat has been gobbled up by a Dutch rival. Now there could be further consolidation in the sector
